<DOC>
	<DOC>NCT00972374</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.</brief_summary>
	<brief_title>Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function</brief_title>
	<detailed_description />
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>The maculaoff retinal detachment must have been caused by a rupture (rhegmatogenous in etiology) The repair of the maculaoff retinal detachment must have occurred at least 6 months before the Day 1 visit in the study eye The repair must have been deemed an anatomic success and required no more than one macular reattachment procedure The visual acuity score must be between 20/50 and 20/320 in the study eye Any sightthreatening ocular condition in the study eye other than the ruptured retinal detachment Anticipated need for ocular surgery during the 12month study period Any injectable, periocular, or intravitreal corticosteroid treatment to study eye within 6 months prior to screening (eg, triamcinolone acetonide) Any injectable, periocular, or intravitreal antiVEGF treatment to the study eye within 3 months prior to screening (eg, Avastin or Lucentis) Any infectious condition in the study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>